Tag Archives: PCSK9

November, 2018

March, 2017

November, 2016

  • 1 November

    Pfizer Discontinues Development of its Investigational PCSK9 Inhibitor

    Tuesday, November 1, 2016 – 6:30am EDT — Pfizer Inc. announced today the discontinuation of the global clinical development program for bococizumab, its investigational Proprotein Convertase Subtilisin Kexin type 9 inhibitor (PCSK9i). The totality of clinical information now available for bococizumab, taken together with the evolving treatment and market landscape for …

October, 2016

August, 2016

  • 31 August

    The Medicines Company Provides Update on Dyslipidemia Programs

    PARSIPPANY, N.J.–(BUSINESS WIRE)–The Medicines Company (NASDAQ:MDCO) today provided an update on its clinical dyslipidemia research programs for MDCO-216 (which contains APoA-1 Milano) and PCSK9si (PCSK9 synthesis inhibitor). MDCO-216. A planned, interim analysis of the first 40 randomized patients completing treatment in the MILANO-PILOT study of MDCO-216 has been reviewed by …

July, 2016

  • 11 July

    FDA Approves Amgen’s Single Monthly Injection for a PCSK9 Inhibitor

    THOUSAND OAKS, Calif., July 11, 2016 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the Repatha® (evolocumab) Pushtronex™ system (on-body infusor with prefilled cartridge), a new, monthly single-dose administration option.1 The Pushtronex system is a hands-free device designed to provide 420 …

May, 2016

August, 2015

  • 28 August

    FDA Approves Amgen’s PCSK9 Inhibitor Repatha

    The U.S. Food and Drug Administration today approved Repatha (evolocumab) injection for some patients who are unable to get their low-density lipoprotein (LDL) cholesterol under control with current treatment options. Repatha, the second drug approved in a new class of drugs known as PCSK9 inhibitors, is approved for use in addition to …

July, 2015

  • 31 July

    FDA Approves Sanofi’s PCSK9 Drug Praluent

    PARIS and TARRYTOWN, N.Y., July 24, 2015 /PRNewswire/ — Sanofi and Regeneron Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved Praluent® (alirocumab) Injection, the first FDA-approved treatment in a new class of drugs known as PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors. Praluent is indicated as …

March, 2015